Expert Review of Gastroenterology & Hepatology最新文献_第2页

Short bowel syndrome-associated intestinal failure: diagnosis and prognosis. 短肠综合征相关肠衰竭：诊断和预后。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-17 DOI: 10.1080/17474124.2026.2646296

John K DiBaise

{"title":"Short bowel syndrome-associated intestinal failure: diagnosis and prognosis.","authors":"John K DiBaise","doi":"10.1080/17474124.2026.2646296","DOIUrl":"10.1080/17474124.2026.2646296","url":null,"abstract":"Introduction: Short bowel syndrome is characterized by severe intestinal malabsorption of macronutrients, micronutrients, fluid, and electrolytes. As such, short bowel syndrome often results in permanent need of parenteral support, that is, intestinal failure. To optimize patient outcomes, it is important to establish precise definitions of short bowel syndrome and intestinal failure. Classifying those with SBS can provide useful prognostic, risk and therapeutic implications.Areas covered: This narrative review will focus on the diagnosis and prognosis of this rare condition. A literature search was performed utilizing PubMed and reviewed references from applicable manuscripts primarily between 2000 and September 2025.Expert opinion: Short bowel syndrome in adults is a clinical malabsorptive syndrome associated with having <200 cm of residual small bowel in continuity, measured from the duodenojejunal flexure. Intestinal failure is the reduction of gut function below the minimum required for the absorption of macronutrients and/or water and electrolytes, thereby requiring parenteral support to maintain health and/or growth. The remaining small bowel length and segment, and health of the remnant bowel have important prognostic implications. Care gaps exist regarding the diagnosis and management of this condition and future efforts should address these disparities in order to provide optimal care to these patients.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"313-323"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147443044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Irritable bowel syndrome in the elderly: epidemiology, diagnosis, treatment, and relationship with frailty. 老年人肠易激综合征：流行病学、诊断、治疗及其与虚弱的关系。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 DOI: 10.1080/17474124.2026.2651944

Derrick M Van Rooyen, Mingshu Cai, Balakrishnan R Nair, Nicholas J Talley

{"title":"Irritable bowel syndrome in the elderly: epidemiology, diagnosis, treatment, and relationship with frailty.","authors":"Derrick M Van Rooyen, Mingshu Cai, Balakrishnan R Nair, Nicholas J Talley","doi":"10.1080/17474124.2026.2651944","DOIUrl":"10.1080/17474124.2026.2651944","url":null,"abstract":"Introduction: Irritable bowel syndrome (IBS) is a common problem in elderly patients defined as over the age of 65 years, and presents unique clinical challenges that distinguish it from IBS in younger populations.Areas covered: Here, we emphasize the need for age-specific approaches to optimize clinical outcomes. An inverse relationship exists between age and IBS prevalence, which may be due to reduced intestinal visceral hypersensitivity or lower levels of anxiety in older people affected. Although the prevalence of IBS in the elderly is lower than in younger populations, it may be rising due to demographic shifts and increasing life expectancy. Emerging evidence indicates IBS is a risk factor for frailty syndrome, driven by multiple factors, which may, in turn, perpetuate IBS. This review covers a broad range of applicable comparative studies, including observational and population studies, as well as randomized controlled trials and meta-analyses, dating back to 1992.Expert opinion: IBS likely contributes to functional decline in the elderly, thereby leading to increased frailty, promoting a self-perpetuating cycle of deteriorating health outcomes. This highlights the importance of incorporating frailty assessment when managing older patients with IBS because early identification and intervention can potentially improve IBS management, and also serve as an outcome measure.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1-14"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147520349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Key mistakes in alcohol-associated liver disease management and how to avoid them: a narrative review. 酒精相关性肝病管理中的主要错误及如何避免：叙述性回顾

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-28 DOI: 10.1080/17474124.2026.2649801

Madunil Anuk Niriella, Renisha Chrismi Karunanayake, Mananjala Sudul Senanayake, Uditha Bandara Dassanayake, Chamara Wijesinghe, Hithanadura Janaka de Silva

{"title":"Key mistakes in alcohol-associated liver disease management and how to avoid them: a narrative review.","authors":"Madunil Anuk Niriella, Renisha Chrismi Karunanayake, Mananjala Sudul Senanayake, Uditha Bandara Dassanayake, Chamara Wijesinghe, Hithanadura Janaka de Silva","doi":"10.1080/17474124.2026.2649801","DOIUrl":"10.1080/17474124.2026.2649801","url":null,"abstract":"Introduction: Alcohol-associated liver disease (ALD) encompasses a spectrum from simple steatosis through fibrosis, cirrhosis, and hepatocellular carcinoma. Alcohol-associated hepatitis (AH) represents a severe acute manifestation of ALD carrying substantial short-term mortality. ALD is strongly associated with harmful alcohol use and alcohol use disorder (AUD), though a proportion of patients may engage in hazardous drinking patterns that do not meet full DSM-5 criteria for AUD. Despite being a considerable global health burden, ALD frequently remains underdiagnosed until advanced stages.Areas covered: This narrative review examines critical deficiencies in the management of ALD and AUD, from initial recognition through long-term follow-up. This review is informed by structured searches of PubMed/MEDLINE, Embase, and Cochrane Library (2005-2025). Commonly identified pitfalls include delayed screening for AUD, inadequate assessment of consumption patterns, mismanagement of episodes of AH, neglect of nutritional requirements, suboptimal pharmacological approaches, and poor coordination among multidisciplinary teams (MDT). By highlighting recurrent mistakes and providing evidence-based strategies to avoid them, this narrative review aims to equip clinicians with practical tools to improve patient outcomes.Expert opinion: The future of ALD management lies at the intersection of technological innovation, therapeutic advancement, systems-level care redesign, and public health policy.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"353-367"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving role of futibatinib for advanced cholangiocarcinoma. 福替替尼在晚期胆管癌中的作用。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-25 DOI: 10.1080/17474124.2026.2649804

Mara Persano, Andrea Casadei-Gardini, Silvia Camera, Margherita Rimini

{"title":"The evolving role of futibatinib for advanced cholangiocarcinoma.","authors":"Mara Persano, Andrea Casadei-Gardini, Silvia Camera, Margherita Rimini","doi":"10.1080/17474124.2026.2649804","DOIUrl":"10.1080/17474124.2026.2649804","url":null,"abstract":"Introduction: Cholangiocarcinoma (CCA) continues to be classified as a rare cancer with high mortality rates, underscoring the urgent need for more effective systemic treatment strategies. The widespread implementation of next-generation sequencing has enabled comprehensive characterization of the genomic landscape of CCA, revealing a relatively high prevalence of actionable genetic alterations.Areas covered: In this evolving therapeutic context, futibatinib has gained attention as a selective, irreversible pan-fibroblast growth factor receptor (FGFR) inhibitor that covalently binds to the FGFR kinase domain, thereby maintaining inhibitory activity against a broad spectrum of FGFR2 resistance mutations. This distinct mechanism of action represents a significant advancement over earlier reversible inhibitors and provides a strong biological rationale for its use in patients with FGFR2-altered CCA. A comprehensive literature search was performed in PubMed/MEDLINE, Embase, and Scopus for studies published from January 2000 to February 2026, using combinations of the terms 'cholangiocarcinoma,' 'FGFR2,' 'fibroblast growth factor receptor,' and 'futibatinib.' Relevant clinical trials, translational studies, and review articles were screened for inclusion.Expert opinion: Futibatinib represents the most biologically rational FGFR inhibitor currently available for FGFR2-altered CCA, as it directly addresses the dominant mechanism limiting the efficacy of earlier agent, on-target resistance driven by secondary FGFR2 kinase domain mutations.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"369-379"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ulcerative colitis, frailty, and beyond. 溃疡性结肠炎、身体虚弱等等。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-04-01 Epub Date: 2026-03-18 DOI: 10.1080/17474124.2026.2645570

Yushan Pan, Bharati Kochar

{"title":"Ulcerative colitis, frailty, and beyond.","authors":"Yushan Pan, Bharati Kochar","doi":"10.1080/17474124.2026.2645570","DOIUrl":"10.1080/17474124.2026.2645570","url":null,"abstract":"Introduction: Frailty is a geriatric construct that is increasingly pertinent to patients with ulcerative colitis (UC). Understanding how frailty and UC interact will be imperative to incorporating frailty into clinical decision-making in UC.Areas covered: This article reviews the definition of frailty and its contributing factors. We review the mechanisms in which UC leads to frailty and the current literature on the impact of frailty status in UC disease course. This review was conducted through PubMed searches using the terms 'ulcerative colitis,' 'frailty,' 'sarcopenia,' 'inflammation,' 'multimorbidity,' and 'aging' with no time restrictions.Expert opinion: Frailty is a prevalent feature in UC and is partly mediated by the chronic inflammation and sarcopenia that characterize UC. Preliminary evidence suggests that frailty may prognosticate outcomes in patients with UC, but more work is needed to define features of frailty pertinent to inflammatory bowel disease, develop and validate measures tailored to assessing frailty in patients with UC, and implement frailty into clinical decision-making for the management of UC.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"303-311"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastric acid secretion therapy: long-term effects on gastric mucosa and polyp formation. 胃酸分泌疗法：对胃黏膜及息肉形成的长期影响。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-26 DOI: 10.1080/17474124.2026.2650654

Hiroko Suda, Koichi Sakurai, Ken Haruma

{"title":"Gastric acid secretion therapy: long-term effects on gastric mucosa and polyp formation.","authors":"Hiroko Suda, Koichi Sakurai, Ken Haruma","doi":"10.1080/17474124.2026.2650654","DOIUrl":"10.1080/17474124.2026.2650654","url":null,"abstract":"Introduction: Proton pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs) are widely used for the management of acid-related disorders. Characteristic gastric mucosal changes have gained clinical attention owing to their widespread and prolonged use.Areas covered: We outline the pharmacological differences between PPIs and P-CABs and we summarize their endoscopic and histological features. Hypergastrinemia is highlighted as a central mediator, interacting with factors including Helicobacter pylori infection, atrophic gastritis, age, and sex. Evidence from randomized and observational studies, case series, and mechanistic investigations has been integrated to provide an overview of the long-term effects of these therapies.Expert opinion: Most reported mucosal alterations, including fundic gland polyps, hyperplastic polyps, multiple white and flat elevated lesions, cracked or cobblestone-like mucosa, black spots, gastric mucosal redness, white spots, and web-like mucus, are considered benign. Although endoscopic surveillance is not currently supported by evidence, awareness of these findings may be useful in patients receiving therapy for several decades. Endoscopic features,-associated with hypergastrinemia and parietal- or enterochromaffin-like cell proliferation, may serve as tools to guide individualized prescribing and deprescribing strategies. Further research should include decade-long cohort studies, studies comparing PPIs and P-CABs, and trials evaluating on-demand and continuous regimens to optimize long-term safety.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"1-13"},"PeriodicalIF":2.5,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-dosage human albumin infusion may be superior for hypervolemic hyponatremia in cirrhosis with ascites. 大剂量人白蛋白输注可能对肝硬化伴腹水的高血容量性低钠血症更有效。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2025-11-17 DOI: 10.1080/17474124.2025.2587292

Xianxian Zhang, Lu Chai, Haonan Zhao, Haitao Zhao, Ran Wang, Mauro Bernardi, Xingshun Qi

{"title":"High-dosage human albumin infusion may be superior for hypervolemic hyponatremia in cirrhosis with ascites.","authors":"Xianxian Zhang, Lu Chai, Haonan Zhao, Haitao Zhao, Ran Wang, Mauro Bernardi, Xingshun Qi","doi":"10.1080/17474124.2025.2587292","DOIUrl":"10.1080/17474124.2025.2587292","url":null,"abstract":"Background: Human albumin (HA) infusion may be effective for improving hypervolemic hyponatremia in cirrhosis. However, it remains unclear about whether HA dosage can influence its efficacy.Methods: Overall, 288 cirrhotic patients with ascites and hypervolemic hyponatremia were retrospectively included and divided into high-dosage (>80 g) and low-dosage (≤80 g) HA groups during the period from the first hyponatremia diagnosis to the last HA infusion. Multivariate logistic regression analyses were performed to explore the impact of HA dosage on hyponatremia and serum albumin (ALB) level, and evaluate the impact of improvement of ALB on hyponatremia. Subgroup analyses were performed according to the baseline serum ALB level.Results: High-dosage HA was independently associated with normalization of hyponatremia (OR = 1.919, p = 0.040) and improvement of ALB (OR = 3.001, p < 0.001). The effect of high-dosage HA on normalization of hyponatremia (OR = 2.108, p = 0.028) and improvement of ALB (OR = 2.926, p = 0.001) remained significant in patients with a baseline ALB level of <30 g/L. Improvement of ALB was independently associated with normalization of hyponatremia (OR = 2.108, p = 0.014). The effect remained significant in patients with a baseline ALB level of <30 g/L (OR = 2.228, p = 0.019).Conclusions: High-dosage HA should be superior to low-dosage HA for correcting hypervolemic hyponatremia in cirrhosis, especially in those with a baseline ALB level of <30 g/L, probably due to its significant benefit in the improvement of ALB.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"289-301"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emerging roles of intestinal organoid models in inflammatory bowel disease research. 肠道类器官模型在炎症性肠病研究中的新作用。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2026-02-22 DOI: 10.1080/17474124.2026.2635421

Steven T Leach, Tess Wheeler, Nerissa Bowcock, Alan Aitchison, Daniel A Lemberg, Andrew S Day

{"title":"The emerging roles of intestinal organoid models in inflammatory bowel disease research.","authors":"Steven T Leach, Tess Wheeler, Nerissa Bowcock, Alan Aitchison, Daniel A Lemberg, Andrew S Day","doi":"10.1080/17474124.2026.2635421","DOIUrl":"10.1080/17474124.2026.2635421","url":null,"abstract":"Introduction: The chronic immune mediated gastrointestinal disease, Inflammatory Bowel Disease (IBD), is increasing in prevalence. However, IBD pathogenesis remains unclear despite decades of research. Therefore, new methods and models of disease are required to gain further insights into IBD pathogenesis. Recent advances in stem cell culture technology now allows for the routine in vitro culture of stem cells derived from an individual. These in vitro stem cells can differentiate into cell-types and cell clusters that resemble the tissue origin of the stem cells. These cell clusters have been termed organoids.Areas covered: Following review of recent available literature, the goal of this review was to specifically focus on intestinal organoids and provide basic methodology of organoid derivation. The review will also discuss the current and potential applications of intestinal organoid models in Gastroenterology research including IBD pathogenesis, host-microbiome interactions, therapeutic response and drug discovery, very-early onset IBD, organ-on-a-chip and bioprinted models.Expert opinion: Organoids offer tangible benefits for improved patient outcomes, particularly with respect to personalized medicine approaches to IBD management.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"247-256"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease - paving a path forward. 口服万古霉素治疗原发性硬化性胆管炎及相关炎症性肠病——铺平了前进的道路。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2026-03-10 DOI: 10.1080/17474124.2026.2635420

Kevin M Johnson, John Grady, Richard Kellermayer, Harland S Winter, James H Tabibian, Cynthia W Buness, Ryan Fischer, Ayesha Shah, Parambir S Dulai, Amol S Rangnekar, Leina Alrabadi, Shamita B Shah, Gerald Holtmann, Laura Räisänen, Peter Lewindon, Ahmad H Ali

{"title":"Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease - paving a path forward.","authors":"Kevin M Johnson, John Grady, Richard Kellermayer, Harland S Winter, James H Tabibian, Cynthia W Buness, Ryan Fischer, Ayesha Shah, Parambir S Dulai, Amol S Rangnekar, Leina Alrabadi, Shamita B Shah, Gerald Holtmann, Laura Räisänen, Peter Lewindon, Ahmad H Ali","doi":"10.1080/17474124.2026.2635420","DOIUrl":"10.1080/17474124.2026.2635420","url":null,"abstract":"Introduction: Primary sclerosing cholangitis (PSC) is a fibro-inflammatory cholangiopathy strongly associated with inflammatory bowel disease (PSC-IBD). With no approved PSC therapy, clinicians face uncertainty about oral vancomycin (OV) as a therapeutic option. This review synthesizes clinical effectiveness evidence alongside mechanistic data.Areas covered: We searched PubMed/Google Scholar for studies of vancomycin in PSC from 1998 through November, 2025. OV shows consistent IBD benefits and variable liver responses. In PSC-IBD, clinical and endoscopic remission occurred in 60% at 6 months and in 71% at 12 months in a pediatric cohort; in an adult single-arm study (n = 15), 80% achieved endoscopic remission at 4 weeks with universal mucosal healing, reductions in fecal calprotectin and Mayo scores, and relapse after withdrawal. For liver disease, a pediatric open-label cohort (n = 45) reported ≥50% declines in gamma-glutamyl transferase in 82%; in an adult pilot randomized controlled trial, alkaline phosphatase fell 46% at 12 weeks. Imaging/histology improved as evidenced by MRCP in 26/34 large-duct PSC and reduced portal/periportal inflammation in 11/12 small-duct PSC. No vancomycin-resistant enterococci development has been reported.Expert opinion: OV appears effective for colitis control in PSC-IBD. Differences in observed liver outcomes across studies likely reflect variation in treatment duration, dose, and endpoint selection. Liver responses may depend on higher doses. Cross-specialty guidance and pragmatic, integrated trials are needed.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"233-246"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging in MASLD. MASLD成像。

IF 2.5 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2026-03-01 Epub Date: 2026-02-28 DOI: 10.1080/17474124.2026.2636184

Sudhakar K Venkatesh

{"title":"Imaging in MASLD.","authors":"Sudhakar K Venkatesh","doi":"10.1080/17474124.2026.2636184","DOIUrl":"10.1080/17474124.2026.2636184","url":null,"abstract":"Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease (CLD) globally, with increasing prevalence and risk of progression to cirrhosis, hepatocellular carcinoma, and liver-related mortality. Early detection and accurate staging are essential to guide interventions as new therapies emerge.Areas covered: This review discusses imaging-based evaluation of MASLD, emphasizing its role in assessing steatosis, fibrosis, and complications of CLD. A literature search of PubMed and Scopus identified peer-reviewed publications from 2000 to the present, including large clinical trials, expert reviews, and major hepatology and imaging guidelines. Key modalities evaluated include ultrasound, computed tomography, and magnetic resonance imaging. Advanced quantitative techniques, such as transient elastography, shear wave elastography, MR elastography, and MRI proton density fat fraction, are summarized. Their role in longitudinal monitoring and prediction of liver-related outcomes is discussed. Advances in ultrasound and emerging imaging biomarkers, including sarcopenia and visceral adiposity, are also briefly discussed.Expert opinion: Imaging is central to precision hepatology in MASLD, enabling comprehensive, noninvasive assessment and integration with clinical data for risk stratification. The integration of clinical data, imaging findings, and elastography will further enhance individualized care and treatment monitoring.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"257-272"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0